Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Clinical indications treated with unregistered antimicrobials: regulatory challenges of antimicrobial resistance and access to effective treatment for patients.

Hillock NT, Paradiso L, Turnidge J, Karnon J, Merlin TL.

Aust Health Rev. 2019 Jul 5. doi: 10.1071/AH18240. [Epub ahead of print]

PMID:
31272525
2.

Just culture: It's more than policy.

Paradiso L, Sweeney N.

Nurs Manage. 2019 Jun;50(6):38-45. doi: 10.1097/01.NUMA.0000558482.07815.ae. No abstract available.

3.

Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.

Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT.

Breast Cancer Res Treat. 2019 Jul;176(1):251. doi: 10.1007/s10549-019-05218-8.

PMID:
30982934
4.

Targeting Glioma Stem Cells by Functional Inhibition of Dynamin 2: A Novel Treatment Strategy for Glioblastoma.

Luwor R, Morokoff AP, Amiridis S, D'Abaco G, Paradiso L, Stylli SS, Nguyen HPT, Tarleton M, Young KA, O'Brien TJ, Robinson PJ, Chircop M, McCluskey A, Jones NC.

Cancer Invest. 2019;37(3):144-155. doi: 10.1080/07357907.2019.1582060. Epub 2019 Mar 25.

PMID:
30907150
5.

Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.

Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT.

Breast Cancer Res Treat. 2019 Jun;175(2):339-351. doi: 10.1007/s10549-019-05166-3. Epub 2019 Mar 2. Erratum in: Breast Cancer Res Treat. 2019 Apr 15;:.

PMID:
30826934
6.

Ponatinib Inhibits Multiple Signaling Pathways Involved in STAT3 Signaling and Attenuates Colorectal Tumor Growth.

Tan FH, Putoczki TL, Lou J, Hinde E, Hollande F, Giraud J, Stylli SS, Paradiso L, Zhu HJ, Sieber OM, Luwor RB.

Cancers (Basel). 2018 Dec 19;10(12). pii: E526. doi: 10.3390/cancers10120526.

7.

E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases.

Babiker HM, Byron SA, Hendricks WPD, Elmquist WF, Gampa G, Vondrak J, Aldrich J, Cuyugan L, Adkins J, De Luca V, Tibes R, Borad MJ, Marceau K, Myers TJ, Paradiso LJ, Liang WS, Korn RL, Cridebring D, Von Hoff DD, Carpten JD, Craig DW, Trent JM, Gordon MS.

Invest New Drugs. 2019 Aug;37(4):636-645. doi: 10.1007/s10637-018-0668-8. Epub 2018 Sep 28.

PMID:
30264293
8.

Inhibition of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using FDA-Approved Drugs.

Whitehead CA, Nguyen HPT, Morokoff AP, Luwor RB, Paradiso L, Kaye AH, Mantamadiotis T, Stylli SS.

Transl Oncol. 2018 Dec;11(6):1406-1418. doi: 10.1016/j.tranon.2018.08.012. Epub 2018 Sep 13.

9.

FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells.

Mima S, Kakinuma C, Higuchi T, Saeki K, Yamada T, Uematsu R, Ishino M, Kito N, Nishikawa H, Kuniyoshi H, Matsumoto T, Fujiwara H, Paradiso LJ, Shimada Y, Iwamura H.

J Pharmacol Exp Ther. 2018 Jul;366(1):125-135. doi: 10.1124/jpet.118.248740. Epub 2018 Apr 13.

PMID:
29653962
10.

A comprehensive meta-analysis of circulation miRNAs in glioma as potential diagnostic biomarker.

Ma C, Nguyen HPT, Luwor RB, Stylli SS, Gogos A, Paradiso L, Kaye AH, Morokoff AP.

PLoS One. 2018 Feb 14;13(2):e0189452. doi: 10.1371/journal.pone.0189452. eCollection 2018.

11.

Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.

Gampa G, Kim M, Cook-Rostie N, Laramy JK, Sarkaria JN, Paradiso L, DePalatis L, Elmquist WF.

Drug Metab Dispos. 2018 May;46(5):658-666. doi: 10.1124/dmd.117.079194. Epub 2018 Feb 2.

12.

Enhancement of invadopodia activity in glioma cells by sublethal doses of irradiation and temozolomide.

Mao L, Whitehead CA, Paradiso L, Kaye AH, Morokoff AP, Luwor RB, Stylli SS.

J Neurosurg. 2018 Sep;129(3):598-610. doi: 10.3171/2017.5.JNS17845. Epub 2017 Nov 17.

PMID:
29148898
13.

Preclinical activity of FF-10501-01, a novel inosine-5'-monophosphate dehydrogenase inhibitor, in acute myeloid leukemia.

Yang H, Fang Z, Wei Y, Bohannan ZS, Gañán-Gómez I, Pierola AA, Paradiso LJ, Iwamura H, Garcia-Manero G.

Leuk Res. 2017 Aug;59:85-92. doi: 10.1016/j.leukres.2017.05.016. Epub 2017 May 26.

PMID:
28599189
14.

Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib.

Areeb Z, Stylli SS, Ware TM, Harris NC, Shukla L, Shayan R, Paradiso L, Li B, Morokoff AP, Kaye AH, Luwor RB.

Med Oncol. 2016 May;33(5):53. doi: 10.1007/s12032-016-0767-3. Epub 2016 Apr 20.

PMID:
27098175
15.

Primary Structural Variation in Anaplasma marginale Msp2 Efficiently Generates Immune Escape Variants.

Graça T, Paradiso L, Broschat SL, Noh SM, Palmer GH.

Infect Immun. 2015 Nov;83(11):4178-84. doi: 10.1128/IAI.00851-15. Epub 2015 Aug 10.

16.

The peroxisome proliferator activated receptor gamma agonist pioglitazone increases functional expression of the glutamate transporter excitatory amino acid transporter 2 (EAAT2) in human glioblastoma cells.

Ching J, Amiridis S, Stylli SS, Bjorksten AR, Kountouri N, Zheng T, Paradiso L, Luwor RB, Morokoff AP, O'Brien TJ, Kaye AH.

Oncotarget. 2015 Aug 28;6(25):21301-14.

17.

Distribution pattern of hepatitis C virus genotypes and correlation with viral load and risk factors in chronic positive patients.

Petruzziello A, Coppola N, Loquercio G, Marigliano S, Giordano M, Azzaro R, Diodato AM, Iervolino V, Di Costanzo G, Di Macchia CA, Di Meo T, Paradiso L, Ferro R, Giuliano P, Russo F, Pasquale G, Cacciapuoti C.

Intervirology. 2014;57(6):311-8. doi: 10.1159/000363386. Epub 2014 Aug 22.

18.

Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells.

Coppola N, De Pascalis S, Pisaturo M, Paradiso L, Macera M, Capoluongo N, Alessio L, Stanzione M, Sagnelli C, Minichini C, Sagnelli E.

J Clin Virol. 2013 Dec;58(4):748-50. doi: 10.1016/j.jcv.2013.09.014. Epub 2013 Sep 23. No abstract available.

PMID:
24140030
19.

Circulating mononuclear progenitor cells: differential roles for subpopulations in repair of retinal vascular injury.

Caballero S, Hazra S, Bhatwadekar A, Li Calzi S, Paradiso LJ, Miller LP, Chang LJ, Kern TS, Grant MB.

Invest Ophthalmol Vis Sci. 2013 Apr 26;54(4):3000-9. doi: 10.1167/iovs.12-10280.

20.

Regulation of glycogen synthase kinase-3 beta (GSK-3β) by the Akt pathway in gliomas.

Atkins RJ, Dimou J, Paradiso L, Morokoff AP, Kaye AH, Drummond KJ, Hovens CM.

J Clin Neurosci. 2012 Nov;19(11):1558-63. doi: 10.1016/j.jocn.2012.07.002. Epub 2012 Sep 19.

PMID:
22999562
21.

Glutamate is associated with a higher risk of seizures in patients with gliomas.

Yuen TI, Morokoff AP, Bjorksten A, D'Abaco G, Paradiso L, Finch S, Wong D, Reid CA, Powell KL, Drummond KJ, Rosenthal MA, Kaye AH, O'Brien TJ.

Neurology. 2012 Aug 28;79(9):883-9. doi: 10.1212/WNL.0b013e318266fa89. Epub 2012 Jul 25.

PMID:
22843268
22.

Stargazin and AMPA receptor membrane expression is increased in the somatosensory cortex of Genetic Absence Epilepsy Rats from Strasbourg.

Kennard JT, Barmanray R, Sampurno S, Ozturk E, Reid CA, Paradiso L, D'Abaco GM, Kaye AH, Foote SJ, O'Brien TJ, Powell KL.

Neurobiol Dis. 2011 Apr;42(1):48-54. doi: 10.1016/j.nbd.2011.01.003. Epub 2011 Jan 8.

PMID:
21220022
23.

Genetic absence epilepsy rats from Strasbourg have increased corticothalamic expression of stargazin.

Powell KL, Kyi M, Reid CA, Paradiso L, D'Abaco GM, Kaye AH, Foote SJ, O'Brien TJ.

Neurobiol Dis. 2008 Aug;31(2):261-5. doi: 10.1016/j.nbd.2008.04.012. Epub 2008 May 10.

PMID:
18556211
24.

Differential coding potential of ADAM22 mRNAs.

Gödde NJ, D'Abaco GM, Paradiso L, Novak U.

Gene. 2007 Nov 15;403(1-2):80-8. Epub 2007 Aug 23.

PMID:
17884303
25.

Making sure the residents get their tablets: medication administration in care homes for older people.

Barnes L, Cheek J, Nation RL, Gilbert A, Paradiso L, Ballantyne A.

J Adv Nurs. 2006 Oct;56(2):190-9.

PMID:
17018067
26.

Efficient ADAM22 surface expression is mediated by phosphorylation-dependent interaction with 14-3-3 protein family members.

Gödde NJ, D'Abaco GM, Paradiso L, Novak U.

J Cell Sci. 2006 Aug 15;119(Pt 16):3296-305. Epub 2006 Jul 25.

27.

ADAM22, expressed in normal brain but not in high-grade gliomas, inhibits cellular proliferation via the disintegrin domain.

D'Abaco GM, Ng K, Paradiso L, Godde NJ, Kaye A, Novak U.

Neurosurgery. 2006 Jan;58(1):179-86; discussion 179-86.

PMID:
16385342
28.

Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor.

Hande KR, Collier M, Paradiso L, Stuart-Smith J, Dixon M, Clendeninn N, Yeun G, Alberti D, Binger K, Wilding G.

Clin Cancer Res. 2004 Feb 1;10(3):909-15.

29.

Overexpression of hyaluronan synthase-2 reduces the tumorigenic potential of glioma cells lacking hyaluronidase activity.

Enegd B, King JA, Stylli S, Paradiso L, Kaye AH, Novak U.

Neurosurgery. 2002 Jun;50(6):1311-8.

PMID:
12015850
30.

Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034.

Bissett D, McLeod HL, Sheedy B, Collier M, Pithavala Y, Paradiso L, Pitsiladis M, Cassidy J.

Br J Cancer. 2001 Feb 2;84(3):308-12.

31.

Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034.

McLeod HL, Cassidy J, Powrie RH, Priest DG, Zorbas MA, Synold TW, Shibata S, Spicer D, Bissett D, Pithavala YK, Collier MA, Paradiso LJ, Roberts JD.

Clin Cancer Res. 2000 Jul;6(7):2677-84.

32.

Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks.

Roberts JD, Shibata S, Spicer DV, McLeod HL, Tombes MB, Kyle B, Carroll M, Sheedy B, Collier MA, Pithavala YK, Paradiso LJ, Clendeninn NJ.

Cancer Chemother Pharmacol. 2000;45(5):423-7.

PMID:
10803927
33.

Differential ability of SOCS proteins to regulate IL-6 and CSF-1 induced macrophage differentiation.

Novak U, Marks D, Nicholson SE, Hilton D, Paradiso L.

Growth Factors. 1999;16(4):305-14.

PMID:
10427504
34.

STAT3 forms stable homodimers in the presence of divalent cations prior to activation.

Novak U, Ji H, Kanagasundaram V, Simpson R, Paradiso L.

Biochem Biophys Res Commun. 1998 Jun 29;247(3):558-63.

PMID:
9647732
35.

CSF-1 and interferon-gamma act synergistically to promote differentiation of FDC-P1 cells into macrophages.

Novak U, Nicholson S, Bourette RP, Rohrschneider LR, Alexander W, Paradiso L.

Growth Factors. 1998;15(3):159-71.

PMID:
9570038
36.

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ.

J Clin Oncol. 1997 Mar;15(3):987-93.

PMID:
9060537
37.

Requirement for Y706 of the murine (or Y708 of the human) CSF-1 receptor for STAT1 activation in response to CSF-1.

Novak U, Nice E, Hamilton JA, Paradiso L.

Oncogene. 1996 Dec 19;13(12):2607-13.

PMID:
9000134
38.
39.

Lack of effect of corticosteroids and tamoxifen on suramin protein binding and in vitro activity.

Driscoll DL, Steinkampf RW, Paradiso LJ, Kowal CD, Klohs WD.

Eur J Cancer. 1996 Feb;32A(2):311-5.

PMID:
8664047
40.

Aberrant activation of JAK/STAT pathway components in response to G-CSF, interferon-alpha/beta and interferon-gamma in NFS-60 cells.

Novak U, Ward AC, Hertzog PJ, Hamilton JA, Paradiso L.

Growth Factors. 1996;13(3-4):251-60.

PMID:
8919032
41.

Colony-stimulating factor 1-induced STAT1 and STAT3 activation is accompanied by phosphorylation of Tyk2 in macrophages and Tyk2 and JAK1 in fibroblasts.

Novak U, Harpur AG, Paradiso L, Kanagasundaram V, Jaworowski A, Wilks AF, Hamilton JA.

Blood. 1995 Oct 15;86(8):2948-56.

PMID:
7579387
42.

Identification of proteins in DNA-protein complexes after blotting of EMSA gels.

Novak U, Paradiso L.

Biotechniques. 1995 Jul;19(1):54-5. No abstract available.

PMID:
7669296
43.

Regulation of the urokinase gene by the retinoblastoma protein.

Novak U, Paradiso L, Hamilton JA.

DNA Cell Biol. 1994 Nov;13(11):1063-9.

PMID:
7702750
44.

Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group.

Talbot GH, Cassileth PA, Paradiso L, Correa-Coronas R, Bond L.

Antimicrob Agents Chemother. 1993 Mar;37(3):474-82.

45.

Secondary syphilis treated with parenteral cephalosporin.

Parish LC, Paradiso L, Witkowski JA.

Int J Dermatol. 1989 Jan-Feb;28(1):58. No abstract available.

PMID:
2917813
46.

Supplemental Content

Loading ...
Support Center